Clinical trial · Observational
Molecular and Epidemiological Characteristics of Endometrial Cancer in Brazil
NCT06014580CI-TRIAL-00124061MADONNAcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
An evaluation of the molecular and epidemiological aspects of endometrial cancer in Brazil is necessary to understand the high frequency of advanced disease. A better understanding of the current situation will generate essential data for the future development of national or international cooperative programs that aim to improve outcomes in these patients and generate additional knowledge for much-needed clinical trials in this population.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Endometrial Cancer | Malignant Endometrial Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Observational study | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients diagnosed with endometrial cancer
- description
- Patients diagnosed with endometrial cancer between January 2016 and December 2019 at participating sites will be included.
- interventionNames
- Other: Observational study
Primary outcomes (4)
- measure
- Epidemiological Characteristics of the Brazilian Population with Endometrial Cancer
- timeFrame
- At the time of diagnosis.
- description
- This measure encompasses key epidemiological factors of the Brazilian population diagnosed with endometrial cancer, including age distribution, racial and ethnic demographics, geographic regions, and relevant comorbidities. These details will provide insights into the demographic makeup of the study population.
- measure
- Molecular Profile Analysis of Endometrial Cancer Cases
- timeFrame
- Throughout the study period, an average of 36 month.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Women ≥18 years * Histological diagnosis of endometrial carcinoma. * Diagnosis of endometrial cancer between January 2016 and December 2019. * FIGO (International Federation of Gynecology and Obstetrics, 2018) Stage I - IV. * Site and investigator with access to a medical record chart from which data can be abstracted. * Presence of a sample of tumor tissue (primary tumor or metastasis) available for biomarker testing. Exclusion Criteria: * Noninvasive endometrial cancer. * Patients with a history of concurrent or previously treated non-endometrial malignancies except for appropriately treated 1) non -metastatic non-melanoma skin cancer and/or 2) non-metastatic low-grade thyroid tumors and/or 3) in situ carcinomas, including cervix, colon, and skin. * Nonepithelial histology (leiomyosarcoma, adenosarcoma, endometrial stromal sarcoma, undifferentiated sarcoma, or other mesenchymal tumors.
References
Publications (0)
Data not yet available
No reference posted for this study.